Indaptus Therapeutics, INC. (INDP) — SEC Filings

Overview

Indaptus Therapeutics, INC. (INDP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 23, 2026: Indaptus Therapeutics, Inc. filed an 8-K on April 23, 2026, reporting changes in directors or officers and compensatory arrangements. The filing also includes financial statements and exhibits, with specific details likely contained within the attached documents EX-10.1 and EX-10.2.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 4 bearish, 34 neutral. The dominant filing sentiment for Indaptus Therapeutics, INC. is neutral.

Filing Type Overview

Indaptus Therapeutics, INC. (INDP) has filed 23 8-K, 5 10-Q, 1 S-1/A, 3 S-1, 3 DEF 14A, 1 SC 13D/A, 1 SC 13D, 1 10-K with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Indaptus Therapeutics Files 8-K on Officer Changes and Exhibits — 8-K · Apr 23, 2026 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on April 23, 2026, reporting changes in directors or officers and compensatory arrangements. The filing also includes f
• 8-K Filing — 8-K · Apr 3, 2026
• Indaptus Therapeutics Reports Key Corporate Events — 8-K · Dec 23, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on December 22, 2025, reporting several material events. These include entering into a material definitive agreement, u
• Indaptus Therapeutics Faces Going Concern Doubt Amid Rising R&D Costs — 10-Q · Nov 12, 2025 Risk: high
  Indaptus Therapeutics, Inc. (INDP) reported a net loss of $12.7 million for the nine months ended September 30, 2025, an increase from a net loss of $10.9 milli
• Indaptus Therapeutics Files 8-K — 8-K · Sep 4, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting on other events and financial statements. The company, formerly known as Intec Parent I
• Indaptus Amends S-1, Reveals Recent Capital Raises Totaling Millions — S-1/A · Sep 3, 2025 Risk: high
  Indaptus Therapeutics, Inc. (INDP) filed an S-1/A on September 3, 2025, primarily to include an Engagement Agreement with H.C. Wainwright & Co., LLC. The compan
• Indaptus Launches Best-Efforts Offering of Stock, Warrants — S-1 · Sep 2, 2025 Risk: high
  Indaptus Therapeutics, Inc. (INDP) is offering up to 781,250 shares of common stock, along with various warrants, in a best-efforts offering. The assumed combin
• Indaptus Therapeutics Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Indaptus Therapeutics Files 8-K on Equity Sales & Shareholder Votes — 8-K · Jul 29, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on July 29, 2025, reporting unregistered sales of equity securities and submission of matters to a vote of security hol
• Indaptus Therapeutics Files 8-K Under 'Other Events' — 8-K · Jul 16, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on July 16, 2025, reporting an event on July 14, 2025. The filing is categorized under 'Other Events' and does not spec
• Indaptus Therapeutics Files 8-K with Financial Obligations — 8-K · Jul 1, 2025 Risk: medium
  On June 30, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported un
• Indaptus Therapeutics Files 8-K on Security Holder Rights — 8-K · Jun 26, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting material modifications to security holder rights and amendments to its articles of incorpor
• Indaptus Seeks Shareholder Nod for Private Placement to Meet Nasdaq Rules — DEF 14A · Jun 23, 2025 Risk: medium
  Indaptus Therapeutics, Inc. (INDP) is holding a Special Meeting of Stockholders on July 25, 2025, at 10:00 a.m. Eastern time, at its New York City offices. The
• Indaptus Therapeutics Files 8-K: New Obligations & Equity Sales — 8-K · Jun 13, 2025 Risk: medium
  On June 12, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filin
• Indaptus Therapeutics Files 8-K — 8-K · Jun 11, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing doe
• Indaptus Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Intec Parent Inc., is incorporated i
• Indaptus Therapeutics Executive Compensation Details — DEF 14A · Apr 28, 2025 Risk: medium
  Indaptus Therapeutics, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
• Indaptus Therapeutics Files 8-K on Financials — 8-K · Mar 13, 2025 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Indaptus Therapeutics Files 8-K on Agreements — 8-K · Feb 12, 2025 Risk: medium
  On February 12, 2025, Indaptus Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The
• Indaptus Therapeutics Fails Nasdaq Listing Standards — 8-K · Jan 31, 2025 Risk: high
  Indaptus Therapeutics, Inc. filed an 8-K on January 31, 2025, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The co
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 14, 2025 Risk: medium
  On January 12, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The
• Indaptus Therapeutics Files S-1 with SEC — S-1 · Dec 23, 2024 Risk: medium
  Indaptus Therapeutics, Inc. filed an S-1 registration statement with the SEC on December 23, 2024. The company, formerly known as Intec Parent Inc. until April
• Meckler Amends Indaptus Therapeutics Stake Filing — SC 13D/A · Nov 26, 2024 Risk: medium
  Jeffrey A. Meckler, filing an amendment (No. 1) to Schedule 13D on November 26, 2024, reports changes in beneficial ownership of Indaptus Therapeutics, Inc. com
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 22, 2024 Risk: medium
  Indaptus Therapeutics, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sale
• Indaptus Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: low
  Indaptus Therapeutics, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as Intec Parent Inc. until April 14
• Indaptus Therapeutics Terminates Merger with 03 Life Sciences — 8-K · Oct 22, 2024 Risk: medium
  On October 17, 2024, Indaptus Therapeutics, Inc. announced the termination of its previously announced merger agreement with 03 Life Sciences, Inc. The terminat
• Meckler Files SC 13D for Indaptus Therapeutics — SC 13D · Oct 10, 2024 Risk: medium
  Jeffrey A. Meckler, filing on behalf of Indaptus Therapeutics, Inc., has submitted a Schedule 13D filing on October 10, 2024. This filing relates to the common
• Indaptus Therapeutics Files S-1 for Security Registration — S-1 · Sep 12, 2024 Risk: medium
  Indaptus Therapeutics, Inc. filed an S-1 registration statement on September 12, 2024, to register securities under the Securities Act of 1933. The company, for
• Indaptus Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  Indaptus Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its operations. S
• Indaptus Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 8, 2024 Risk: medium
  On August 7, 2024, Indaptus Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are not detailed in this filing. The company
• Indaptus Therapeutics Holds Annual Meeting, Elects Directors — 8-K · Jun 7, 2024 Risk: low
  Indaptus Therapeutics, Inc. announced on June 6, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders elected two Class
• Indaptus Therapeutics Files 8-K — 8-K · May 22, 2024 Risk: low
  Indaptus Therapeutics, Inc. filed an 8-K on May 22, 2024, reporting an event under 'Other Events'. The company, formerly known as Intec Parent Inc. until April
• Indaptus Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
  Indaptus Therapeutics, Inc. (INDP) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Indaptus Therapeutics, Inc. filed a 10-Q for the quarterly perio
• Indaptus Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk: low
  Indaptus Therapeutics, Inc. (INDP) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Indaptus Therap
• Indaptus Therapeutics to be Acquired by 03 Life Sciences — 8-K · Mar 25, 2024 Risk: medium
  Indaptus Therapeutics, Inc. announced on March 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is
• Indaptus Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 13, 2024 Risk:
  Indaptus Therapeutics, Inc. (INDP) filed a Annual Report (10-K) with the SEC on March 13, 2024. Indaptus Therapeutics, Inc. filed its 2023 Form 10-K on March 13
• Indaptus Therapeutics Relocates HQ — 8-K · Mar 4, 2024 Risk: low
  On March 4, 2024, Indaptus Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3 Columbus Circ
• Indaptus Therapeutics Files Routine 8-K; No Major Changes Reported — 8-K · Jan 23, 2024
  Indaptus Therapeutics, Inc. filed an 8-K on January 23, 2024, reporting an event on January 22, 2024. This filing is a routine current report, indicating no maj

Risk Profile

Risk Assessment: Of INDP's 35 recent filings, 4 were flagged as high-risk, 19 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Indaptus Therapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: -$12.7 million
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $5.8 million
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Jeffrey A. Meckler
• Gary Emmanuel, Esq.
• Rick A. Werner, Esq.
• Jayun Koo, Esq.
• Nir Sassi
• Gary Emmanuel, Esq
• 0001506916
• Peter N. Handrino

Industry Context

Indaptus Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutic candidates like Decoy20. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on clinical trial outcomes, regulatory approvals, and market adoption, all of which are subject to substantial uncertainty.

Top Tags

equity-sale (7) · material-agreement (5) · corporate-action (4) · Biotechnology (4) · 10-Q (4) · pharmaceuticals (4) · Warrants (3) · 8-k (3) · corporate-governance (3) · sec-filing (3)

Key Numbers

• Net loss: $12.7 million — For the nine months ended September 30, 2025, an increase from $10.9 million in 2024.
• Accumulated deficit: $73.2 million — As of September 30, 2025, indicating significant historical losses.
• Cash and cash equivalents: $5.8 million — As of September 30, 2025, providing a short operational runway.
• Cash used in operating activities: $11.6 million — For the nine months ended September 30, 2025, demonstrating high burn rate.
• Research and development expenses: $6.5 million — For the nine months ended September 30, 2025, up from $4.8 million in 2024.
• Net proceeds from SEPA: $1.75 million — Raised during the nine months ended September 30, 2025.
• Gross proceeds from convertible notes: $5.7 million — Raised in June 2025.
• Gross proceeds from ATM Agreement: $2.34 million — Raised in September 2025.
• Shares outstanding: 1,751,163 — As of November 11, 2025, after a 1-for-28 reverse stock split on June 27, 2025.
• SEC File Number: 001-40652 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 86-3158720 — Company's tax identification number.
• Aggregate principal amount of convertible notes: $5.7 million — Sold in June 2025 private placement
• Shares of common stock: 501,566 — Converted from convertible notes at $8.302 per share in June 2025
• Warrants to purchase common stock: 1,384,722 — Issued in June 2025 private placement
• Maximum amount under Standby Equity Purchase Agreement (SEPA): $20.0 million — Agreement with YA II PN, LTD. from February 2025

Frequently Asked Questions